These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23803109)

  • 1. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
    BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda.
    Habyarimana T; Attaleb M; Mugenzi P; Mazarati JB; Bakri Y; El Mzibri M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):375-379. PubMed ID: 29479983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
    Hallamies S; Pelttari LM; Poikonen-Saksela P; Jekunen A; Jukkola-Vuorinen A; Auvinen P; Blomqvist C; Aittomäki K; Mattson J; Nevanlinna H
    BMC Cancer; 2017 Sep; 17(1):620. PubMed ID: 28874143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
    Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
    Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
    Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
    J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
    Choi DH; Cho DY; Lee MH; Park HS; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2008 Dec; 112(3):569-73. PubMed ID: 18175216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
    Serrano-Fernández P; Debniak T; Górski B; Bogdanova N; Dörk T; Cybulski C; Huzarski T; Byrski T; Gronwald J; Wokołorczyk D; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2009 Sep; 117(1):161-5. PubMed ID: 19030985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.